Aptose Biosciences Inc (NASDAQ:APTO) (TSE:APS) has been assigned an average recommendation of “Hold” from the six brokerages that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $6.00.
Several equities analysts have weighed in on APTO shares. HC Wainwright set a $4.00 target price on shares of Aptose Biosciences and gave the company a “buy” rating in a report on Monday, October 30th. Roth Capital restated a “buy” rating and set a $5.00 target price on shares of Aptose Biosciences in a report on Monday, October 23rd. Zacks Investment Research upgraded shares of Aptose Biosciences from a “hold” rating to a “buy” rating and set a $2.00 target price for the company in a report on Friday, November 17th. Canaccord Genuity set a $7.00 target price on shares of Aptose Biosciences and gave the company a “buy” rating in a report on Wednesday, November 15th. Finally, ValuEngine upgraded shares of Aptose Biosciences from a “strong sell” rating to a “sell” rating in a report on Tuesday, October 31st.
A hedge fund recently raised its stake in Aptose Biosciences stock. Acadian Asset Management LLC raised its holdings in shares of Aptose Biosciences Inc (NASDAQ:APTO) (TSE:APS) by 316.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 44,421 shares of the biotechnology company’s stock after acquiring an additional 33,766 shares during the quarter. Acadian Asset Management LLC owned approximately 0.17% of Aptose Biosciences worth $100,000 as of its most recent filing with the Securities and Exchange Commission. 0.92% of the stock is owned by institutional investors.
Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last announced its quarterly earnings data on Tuesday, November 14th. The biotechnology company reported ($0.11) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.13) by $0.02. research analysts expect that Aptose Biosciences will post -0.61 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: This report was reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be viewed at https://www.americanbankingnews.com/2018/02/14/aptose-biosciences-inc-apto-given-average-rating-of-hold-by-brokerages.html.
About Aptose Biosciences
Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.